Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZFGN
CUSIPN/A
Phone617-622-4003
Debt
Debt-to-Equity Ratio0.31
Current Ratio12.27
Quick Ratio12.27
Price-To-Earnings
Trailing P/E Ratio-3.86
Forward P/E Ratio-2.93
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.85 per share
Price / Book2.57
Profitability
EPS (Most Recent Fiscal Year)($1.90)
Net Income$-52,020,000.00
Net MarginsN/A
Return on Equity-66.22%
Return on Assets-54.53%
Miscellaneous
Employees35
Outstanding Shares27,560,000
Zafgen (NASDAQ:ZFGN) Frequently Asked Questions
What is Zafgen's stock symbol?
Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."
How were Zafgen's earnings last quarter?
Zafgen Inc (NASDAQ:ZFGN) announced its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.06. View Zafgen's Earnings History.
When is Zafgen's next earnings date?
What price target have analysts set for ZFGN?
2 Wall Street analysts have issued 12-month price targets for Zafgen's shares. Their predictions range from $20.00 to $20.00. On average, they expect Zafgen's share price to reach $20.00 in the next year. View Analyst Ratings for Zafgen.
Who are some of Zafgen's key competitors?
Some companies that are related to Zafgen include CymaBay Therapeutics (CBAY), Rhythm Pharmaceuticals (RYTM), ANI Pharmaceuticals Inc Common Stock (ANIP), AMAG Pharmaceuticals (AMAG), Amphastar Pharmaceuticals (AMPH), NuCana (NCNA), Theratechnologies (THERF), Inflarx (IFRX), Vectura Group (VEGPF), Urogen Pharma (URGN), Abeona Therapeutics (ABEO), Arcus Biosciences (RCUS), Odonate Therapeutics (ODT), Homology Medicines (FIXX) and Adamas Pharmaceuticals (ADMS).
Who are Zafgen's key executives?
Zafgen's management team includes the folowing people:
- Dr. Thomas E. Hughes, Pres, Chief Scientific Officer & Director (Age 58)
- Ms. Patricia L. Allen, Chief Financial Officer (Age 56)
- Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 48)
- Mr. Jeffrey S. Hatfield, CEO & Director (Age 60)
- Dr. James E. Vath Ph.D., Head of Discovery and Devel. (Age 57)
Has Zafgen been receiving favorable news coverage?
Press coverage about ZFGN stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zafgen earned a media sentiment score of 0.18 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.78 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Zafgen's major shareholders?
Zafgen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Artal Group S.A. (4.35%), Dimensional Fund Advisors LP (3.14%), Nexthera Capital LP (1.46%), Citadel Advisors LLC (1.14%), Millennium Management LLC (0.66%) and Spark Investment Management LLC (0.38%). Company insiders that own Zafgen stock include Dennis D Kim, Frances K Heller, Patricia L Allen and Thomas E Hughes. View Institutional Ownership Trends for Zafgen.
Which major investors are selling Zafgen stock?
Which major investors are buying Zafgen stock?
ZFGN stock was acquired by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Nexthera Capital LP, Artal Group S.A., Dimensional Fund Advisors LP, Candriam Luxembourg S.C.A., Tibra Equities Europe Ltd, Millennium Management LLC and Algert Global LLC. Company insiders that have bought Zafgen stock in the last two years include Dennis D Kim, Frances K Heller, Patricia L Allen and Thomas E Hughes. View Insider Buying and Selling for Zafgen.
How do I buy shares of Zafgen?
Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zafgen's stock price today?
One share of ZFGN stock can currently be purchased for approximately $7.33.
How big of a company is Zafgen?
Zafgen has a market capitalization of $205.62 million. The biopharmaceutical company earns $-52,020,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 35 workers across the globe.
How can I contact Zafgen?
Zafgen's mailing address is 175 PORTLAND STREET 4TH FLOOR, BOSTON MA, 02114. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]
MarketBeat Community Rating for Zafgen (ZFGN)
MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe ZFGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
